Global Interferon Drug Market Insights, Forecast to 2028

Interferons are a group of signaling proteins made and released by host cells in response to the presence of several viruses. In a typical scenario, a virus-infected cell will release interferons causing nearby cells to heighten their anti-viral defenses.
Market Analysis and Insights: Global Interferon Drug Market
Due to the COVID-19 pandemic, the global Interferon Drug market size is estimated to be worth US$ million in 2022 and is forecast to a readjusted size of US$ million by 2028 with a CAGR of % during the review period. Fully considering the economic change by this health crisis, Long-acting Interferon accounting for % of the Interferon Drug global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR in the post-COVID-19 period. While Hepatitis segment is altered to an % CAGR throughout this forecast period.
China Interferon Drug market size is valued at US$ million in 2021, while the US and Europe Interferon Drug are US$ million and US$ million, severally. The proportion of the US is % in 2021, while China and Europe are % and % respectively, and it is predicted that China proportion will reach % in 2028, trailing a CAGR of % through the analysis period. Japan, South Korea, and Southeast Asia are noteworthy markets in Asia, with CAGR %, %, and % respectively for the next 6-year period. As for the Europe Interferon Drug landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period.
The global key manufacturers of Interferon Drug include Roche, Anke Bio, Bayer, Merck & Co, Tri-Prime Gene, Kawin, Kexing Pharma, Novartis and Biogen, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
Global Interferon Drug Scope and Segment
Interferon Drug market is segmented by Type and by Application. Players, stakeholders, and other participants in the global Interferon Drug market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2017-2028.
Segment by Type
Long-acting Interferon
Common Interferon
Segment by Application
Hepatitis
Multiple Sclerosis
Other
By Company
Roche
Anke Bio
Bayer
Merck & Co
Tri-Prime Gene
Kawin
Kexing Pharma
Novartis
Biogen
Merck KGaA
Zydus Cadila
Huaxin Bio
Hayao
Amoytop
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE